SCHEMBL4813072

SCHEMBL4813072

CCc1nc2c(-c3ccc(Cl)cc3)n(-c3ccccc3Cl)nc2c(=O)n1CC(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813964 0.88 CNR1 (1.00) CNR1
SCHEMBL4816685 0.84 CNR1 (0.84) CNR1
SCHEMBL4814762 0.83 CNR1 (0.84) CNR1
SCHEMBL4816644 0.82 CNR1 (0.87) CNR1
SCHEMBL4813096 0.81 CNR1 (0.85) CNR1
SCHEMBL4819827 0.81 CNR1 (0.85) CNR1
SCHEMBL4819520 0.80 CNR1 (0.80) CNR1
SCHEMBL4818917 0.79 CNR1 (0.82) CNR1
SCHEMBL4822993 0.79 CNR1 (0.78) CNR1
SCHEMBL4822346 0.79 CNR1 (0.82) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141669-B2 Cannabiniod receptor ligands and uses thereof PFIZER INC. (US) 2006-11-28 US claimed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 US claimed
US-7354929-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2008-04-08 US disclosed
US-7354929-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2008-04-08 US disclosed
US-7354929-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2008-04-08 US disclosed
US-20070275964-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER, INC. 2007-11-29 US disclosed
US-7268133-B2 Cannabinoid receptor ligands and uses thereof PFIZER, INC. PATENT DEPARTMENT (US) 2007-09-11 US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 US disclosed
US-7141669-B2 Cannabiniod receptor ligands and uses thereof PFIZER INC. (US) 2006-11-28 US disclosed
EP-1622902-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2006-02-08 EP disclosed
WO-2004094417-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-11-04 WO disclosed
US-20040214837-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-10-28 US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, GPR18 CNR1 1/4885
US-20040214837-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885
US-20070275964-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, GPR18 CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.